Published in J Neural Transm (Vienna) on April 10, 2007
Update on recent molecular and genetic advances in frontotemporal lobar degeneration. J Neuropathol Exp Neurol (2008) 1.08
Intra-familial clinical heterogeneity due to FTLD-U with TDP-43 proteinopathy caused by a novel deletion in progranulin gene (PGRN). J Alzheimers Dis (2010) 0.83
Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology (1998) 26.77
Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature (2006) 11.59
Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature (2006) 9.31
Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration. Hum Mol Genet (2006) 4.80
Frontotemporal dementia in The Netherlands: patient characteristics and prevalence estimates from a population-based study. Brain (2003) 2.20
Progranulin gene mutations associated with frontotemporal dementia and progressive non-fluent aphasia. Brain (2006) 2.00
Histopathological changes underlying frontotemporal lobar degeneration with clinicopathological correlation. Acta Neuropathol (2005) 1.55
Mutations in progranulin explain atypical phenotypes with variants in MAPT. Brain (2006) 1.43
Characteristics of frontotemporal dementia patients with a Progranulin mutation. Ann Neurol (2006) 1.22
Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology (1996) 8.82
Genomic instability in Gadd45a-deficient mice. Nat Genet (1999) 3.01
Limbic encephalitis and small cell lung cancer. Clinical and immunological features. Brain (1997) 2.64
Neuronal surface antigen antibodies in limbic encephalitis: clinical-immunologic associations. Neurology (2008) 2.27
Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. J Clin Oncol (1997) 2.19
Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. Neurology (2000) 2.17
Ictal laughter associated with paroxysmal hypothalamopituitary dysfunction. Epilepsia (1997) 2.14
Effects of bilateral subthalamic stimulation on cognitive function in Parkinson disease. Arch Neurol (2001) 2.06
Total homocysteine in patients with type 1 diabetes. Diabetes Care (2000) 2.04
Clinical, neuropathologic, and genetic studies of a large spinocerebellar ataxia type 1 (SCA1) kindred: (CAG)n expansion and early premonitory signs and symptoms. Neurology (1995) 1.97
Autoantibodies to glutamic acid decarboxylase in three patients with cerebellar ataxia, late-onset insulin-dependent diabetes mellitus, and polyendocrine autoimmunity. Neurology (1997) 1.85
Characteristics of idiopathic REM sleep behavior disorder and that associated with MSA and PD. Neurology (2005) 1.85
A new human gene from the Down syndrome critical region encodes a proline-rich protein highly expressed in fetal brain and heart. Hum Mol Genet (1995) 1.68
Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Carbidopa/Levodopa Study Group. Neurology (1999) 1.67
Brain-derived neurotrophic factor in Huntington disease. Brain Res (2000) 1.57
Study of the localization of iron, ferritin, and hemosiderin in Alzheimer's disease hippocampus by analytical microscopy at the subcellular level. J Struct Biol (2005) 1.55
The role of DAT-SPECT in movement disorders. J Neurol Neurosurg Psychiatry (2010) 1.53
Homocysteine and the MTHFR 677C-->T allele in premature coronary artery disease. Case control and family studies. Eur J Clin Invest (2001) 1.52
Ubiquitin in cerebral amyloid angiopathy. J Neurol Sci (1992) 1.50
Abnormal synaptic protein expression in two Arabian horses with equine degenerative myeloencephalopathy. Vet J (2003) 1.50
Cyclosporine-associated mutism in liver transplant patients. Neurology (1996) 1.49
Plasmapheresis and antineoplastic treatment in CNS paraneoplastic syndromes with antineuronal autoantibodies. Neurology (1992) 1.47
Obsessive-compulsive symptoms in Parkinson's disease. J Neurol Neurosurg Psychiatry (2001) 1.47
Widespread changes in dendritic spines in a model of Alzheimer's disease. Cereb Cortex (2008) 1.46
BDNF and full-length and truncated TrkB expression in Alzheimer disease. Implications in therapeutic strategies. J Neuropathol Exp Neurol (1999) 1.46
PICOGEN: five years experience with a genetic counselling program for dementia. Neurologia (2010) 1.46
Intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with antineuronal autoantibodies. J Neurol Neurosurg Psychiatry (1996) 1.39
Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease. Neurology (2008) 1.39
Immunological characterization of a neuronal antibody (anti-Tr) associated with paraneoplastic cerebellar degeneration and Hodgkin's disease. J Neuroimmunol (1997) 1.35
The development of parvalbumin-immunoreactivity in the neocortex of the mouse. Brain Res Dev Brain Res (1994) 1.33
Increased frequency of CD4+ CD25+ regulatory T cells in the cerebrospinal fluid but not in the blood of multiple sclerosis patients. Clin Exp Immunol (2007) 1.32
Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder. Sleep Med (2013) 1.31
Decreased numbers of dendritic spines on cortical pyramidal neurons in dementia. A quantitative Golgi study on biopsy samples. Hum Neurobiol (1988) 1.28
The alpha-synuclein gene in multiple system atrophy. J Neurol Neurosurg Psychiatry (2006) 1.25
Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease. Eur J Neurol (2013) 1.24
Significant association between the tau gene A0/A0 genotype and Parkinson's disease. Ann Neurol (2000) 1.22
Pretreatment methods to improve sludge anaerobic degradability: a review. J Hazard Mater (2010) 1.22
Indolent anti-Hu-associated paraneoplastic sensory neuropathy. Neurology (1994) 1.20
Mitochondrial respiratory chain activity in skeletal muscle from patients with Parkinson's disease. Neurology (1993) 1.18
Detection of known and novel genomic rearrangements by array based comparative genomic hybridisation: deletion of ZNF533 and duplication of CHARGE syndrome genes. J Med Genet (2008) 1.17
Early prediction of stroke severity. Role of the erythrocyte sedimentation rate. Stroke (1995) 1.17
Phosphorylation of tau and alpha-synuclein in synaptic-enriched fractions of the frontal cortex in Alzheimer's disease, and in Parkinson's disease and related alpha-synucleinopathies. Neuroscience (2008) 1.16
Towards a method for automated classification of 1H MRS spectra from brain tumours. NMR Biomed (1998) 1.14
The fragile X tremor ataxia syndrome in the differential diagnosis of multiple system atrophy: data from the EMSA Study Group. Brain (2005) 1.14
Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients. Oncogene (1993) 1.14
Comparative analysis of gait in Parkinson's disease, cerebellar ataxia and subcortical arteriosclerotic encephalopathy. Brain (1999) 1.14
Parkinson's disease with depression: a possible subgroup of idiopathic parkinsonism. Neurology (1986) 1.14
Identification of necrotic cell death by the TUNEL assay in the hypoxic-ischemic neonatal rat brain. Neurosci Lett (1997) 1.12
Familial atypical progressive supranuclear palsy associated with homozigosity for the delN296 mutation in the tau gene. Ann Neurol (2001) 1.12
Detection of 14-3-3 brain protein in the cerebrospinal fluid of patients with paraneoplastic neurological disorders. Ann Neurol (1999) 1.11
Characterization of a double (amyloid precursor protein-tau) transgenic: tau phosphorylation and aggregation. Neuroscience (2005) 1.10
Levodopa withdrawal after bilateral subthalamic nucleus stimulation in advanced Parkinson disease. Arch Neurol (2000) 1.08
Hyperintense globus pallidus on T1-weighted MRI in cirrhotic patients is associated with severity of liver failure. Neurology (1993) 1.08
Natural killer cells are required for accelerated type 1 diabetes driven by interferon-beta. Clin Exp Immunol (2008) 1.07
Triptolide induces apoptotic death of T lymphocyte. Immunopharmacology (1998) 1.07
How a neuropsychiatric brain bank should be run: a consensus paper of Brainnet Europe II. J Neural Transm (Vienna) (2006) 1.07
Autosomal recessive Wolfram syndrome associated with an 8.5-kb mtDNA single deletion. Am J Hum Genet (1996) 1.06
Clinical features and APOE genotype of pathologically proven early-onset Alzheimer disease. Neurology (2011) 1.06
Meige syndrome: neuropathology of a case. Mov Disord (1988) 1.05
The European Multiple System Atrophy-Study Group (EMSA-SG). J Neural Transm (Vienna) (2005) 1.05
Abnormal synaptic protein expression and cell death in murine scrapie. Acta Neuropathol (2002) 1.04
Regional cerebral blood flow pattern in normal young and aged volunteers: a 99mTc-HMPAO SPET study. Eur J Nucl Med (1996) 1.04
Normal pubertal development in a female with carbohydrate deficient glycoprotein syndrome. Arch Dis Child (1996) 1.03
Distinctive abnormalities of facial reflexes in patients with progressive supranuclear palsy. Brain (1997) 1.03
Lysosome-associated membrane protein 1 (LAMP-1) in Alzheimer's disease. Neuropathol Appl Neurobiol (2006) 1.03
Clinical outcome of patients with anti-Hu-associated encephalomyelitis after treatment of the tumor. Neurology (1999) 1.02
Expression of mutant ubiquitin (UBB+1) and p62 in myotilinopathies and desminopathies. Neuropathol Appl Neurobiol (2007) 1.02
Modulation of SIRT1 expression in different neurodegenerative models and human pathologies. Neuroscience (2008) 1.02
Postnatal development of parvalbumin and calbindin D28K immunoreactivities in the cerebral cortex of the rat. Anat Embryol (Berl) (1993) 1.00
S-adenosylhomocysteine hydrolase downregulation contributes to tumorigenesis. Carcinogenesis (2008) 1.00
Primary progressive aphasia as the initial manifestation of corticobasal degeneration and unusual tauopathies. Acta Neuropathol (2003) 1.00
Identification of Spanish familial Parkinson's disease and screening for the Ala53Thr mutation of the alpha-synuclein gene in early onset patients. Neurosci Lett (1997) 1.00
Decreased frontal choline and neuropsychological performance in preclinical Huntington disease. Neurology (2007) 1.00
Continuous positive air pressure eliminates nocturnal stridor in multiple system atrophy. Barcelona Multiple System Atrophy Study Group. Lancet (2000) 1.00
Habituation of the auditory startle reaction is reduced during preparation for execution of a motor task in normal human subjects. Brain Res (1997) 1.00
Cavernous angiomas of the cranial nerves. Report of two cases. J Neurosurg (1990) 1.00
A novel PSEN1 mutation (K239N) associated with Alzheimer's disease with wide range age of onset and slow progression. Eur J Neurol (2010) 1.00
On-probe sample pretreatment for the detection of proteins above 15 KDa from whole cell bacteria by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Rapid Commun Mass Spectrom (2000) 0.99
Giant-cell arteritis presenting with ipsilateral hemiplegia and lateral medullary syndrome. Eur Neurol (1989) 0.99
Cerebral atrophy in Parkinson's disease patients with visual hallucinations. Eur J Neurol (2007) 0.99
Cyclin D1 and retinoblastoma gene expression in human breast carcinoma: correlation with tumour proliferation and oestrogen receptor status. J Pathol (1997) 0.99
A Golgi analysis of unlayered polymicrogyria. Acta Neuropathol (1984) 0.99
A golgi and ultrastructural study of a dominant form of Kufs' disease. J Neurol (1980) 0.99
Reactive microglia in the developing brain. Acta Neuropathol (1980) 0.99